Treatment outcome

治疗结果
  • 文章类型: Journal Article
    背景:脊髓肿瘤的微创治疗很常见。这项研究的目的是比较经微内镜微创手术-通过自制管状牵开器(MIS-TR)和显微全椎板切除术(开放手术)治疗的胸髓外脊柱肿瘤(TEST)患者的围手术期结果。
    方法:2016年2月至2021年2月,纳入了51例TEST患者。根据他们的临床数据,将患者分为MIS-TR组(n=30)和开放手术组(n=21)并进行评估.
    结果:在两组中,平均手术时间,围手术期ASIA评分的变化,和改良的Macnab评分具有可比性。MIS-TR组术后平均住院时间明显短于开放手术组(p<0.0001)。MIS-TR组的平均失血量明显低于开放手术组(p=0.001)。MIS-TR组围手术期并发症发生率明显低于开放手术组(p<0.0001)。在3个月的随访中,两组间Oswestry残疾指数(ODI)评分改善无显著差异.尽管如此,在12个月的随访中,MIS-TR组的平均ODI显著低于开放手术组(p=0.023).术后完全恢复的主要影响因素为术前ASIA评分(OR7.848,P=0.002),手术并发症(OR0.017,P=0.008)和年龄(OR0.974,P=0.393)。
    结论:MIS-TR比开放手术治疗TEST更安全有效,但MIS-TR的长期恢复并不比开放手术好。
    BACKGROUND: Minimally invasive treatments for spinal cord tumours are common. The aim of this study was to compare the perioperative outcomes of patients with thoracic extramedullary spinal tumours (TEST) treated by microendoscopic minimally invasive surgery-hemilaminectomy through a homemade tubular retractor (MIS-TR) and microscopic full laminectomy (open surgery).
    METHODS: Between February 2016 and February 2021, 51 patients with TEST were included. According to their clinical data, patients were classified into the MIS-TR group (n = 30) and the open surgery group (n = 21) and assessed.
    RESULTS: In both groups, the mean operation time, change in perioperative ASIA score, and modified Macnab score were comparable. The average postoperative hospital stay in the MIS-TR group was substantially shorter than that in the open surgery group (p < 0.0001). The mean blood loss volume in the MIS-TR group was substantially lower than that in the open surgery group (p = 0.001). The perioperative complication rate in the MIS-TR group was considerably lower than that in the open surgery group (p < 0.0001). At the 3-month follow-up, there was no substantial difference in the Oswestry Disability Index (ODI) score improvement between the two groups. Nonetheless, at the 12-month follow-up, the average ODI in the MIS-TR group was considerably lower than that in the open surgery group (p = 0.023). The main influencing factors for complete postoperative recovery were preoperative ASIA score (OR 7.848, P = 0.002), surgical complications (OR 0.017, P = 0.008) and age (OR 0.974, P = 0.393).
    CONCLUSIONS: MIS-TR is safer and more effective than open surgery for treating TEST, but the long-term recovery of MIS-TR is not better than that of open surgery.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    背景:本研究旨在比较原发性高级别神经胶质瘤(HGG)患者的生存结果和副作用,这些患者单独接受碳离子放疗(CIRT)或作为光子放疗后的增强策略(光子+CIRTboost)。
    方法:三十四(34)例经组织学证实的HGG患者,并单独接受CIRT或光子CIRTboost,在2020.03-2023.08期间在武威市肿瘤医院和研究所同时使用替莫唑胺,对中国进行了回顾性审查。总生存期(OS),无进展生存期(PFS),并对急性毒性和晚期毒性进行了分析和比较。
    结果:8名WHO3级和26名4级患者被纳入分析。对于所有HGG病例,单独CIRT组和光子CIRTboost组的中位PFS分别为15个月和19个月,4级病例分别为15个月和17.5个月。对于所有HGG病例,单独CIRT组和光子CIRTboost组的中位OS分别为28个月和31个月,4级病例分别为21个月和19个月。在单独的CIRT和光子+CIRTboost组之间没有观察到这些生存结果的显著差异。仅在单独的CIRT和光子CIRTboost组中观察到1级急性毒性。与光子+CIRTboost相比,单纯CIRT组的急性毒性比率显著降低(3/18vs.9/16,p=0.03)。没有观察到晚期毒性的显著差异。
    结论:单独使用BothCIRT和光子+CIRTboost同时使用替莫唑胺是安全的,HGG患者的PFS和OS无显著差异。在未来的随机试验中,探讨CIRTboost的剂量递增是否可以改善HGG患者的生存结果是有意义的。
    BACKGROUND: This study aimed to compare the survival outcome and side effects in patients with primary high-grade glioma (HGG) who received carbon ion radiotherapy (CIRT) alone or as a boost strategy after photon radiation (photon + CIRTboost).
    METHODS: Thirty-four (34) patients with histologically confirmed HGG and received CIRT alone or Photon + CIRTboost, with concurrent temozolomide between 2020.03-2023.08 in Wuwei Cancer Hospital & Institute, China were retrospectively reviewed. Overall survival (OS), progression-free survival (PFS), and acute and late toxicities were analyzed and compared.
    RESULTS: Eight WHO grade 3 and 26 grade 4 patients were included in the analysis. The median PFS in the CIRT alone and Photon + CIRTboost groups were 15 and 19 months respectively for all HGG cases, and 15 and 17.5 months respectively for grade 4 cases. The median OS in the CIRT alone and Photon + CIRTboost groups were 28 and 31 months respectively for all HGG cases, and 21 and 19 months respectively for grade 4 cases. No significant difference in these survival outcomes was observed between the CIRT alone and Photon + CIRTboost groups. Only grade 1 acute toxicities were observed in CIRT alone and Photon + CIRTboost groups. CIRT alone group had a significantly lower ratio of acute toxicities compared to Photon + CIRTboost (3/18 vs. 9/16, p = 0.03). No significant difference in late toxicities was observed.
    CONCLUSIONS: Both CIRT alone and Photon + CIRTboost with concurrent temozolomide are safe, without significant differences in PFS and OS in HGG patients. It is meaningful to explore whether dose escalation of CIRTboost might improve survival outcomes of HGG patients in future randomized trials.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Systematic Review
    在急性呼吸道感染领域,冠状病毒病-19(COVID-19),由严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引起,构成全球公共卫生挑战。皮质类固醇(CSs)在COVID-19中的应用仍然是研究人员的争议话题。因此,我们的团队对随机对照试验(RCTs)进行了全面的荟萃分析,以仔细评估CSs在住院COVID-19患者中的安全性和有效性.探讨CSs治疗COVID-19的疗效,我们仔细筛选了关键数据库的RCT,包括PubMed,WebofScience,Embase,科克伦图书馆,ClinicalTrials.gov,以及中国CNKI和万方数据。我们专注于评估28天死亡率。我们使用卡方检验和I2值评估了数据异质性,将显著性设置为0.1%和50%。分析了涉及5721名参与者的21个RCT的数据。分析未显示CSs干预与住院COVID-19患者28天死亡风险之间存在显著关联(相对风险[RR]=0.93;95%置信区间[95%CI]:0.84-1.03;P=0.15)。然而,亚组分析显示,中重度COVID-19患者28日死亡率显著降低(RR为0.85;95%CI:0.76~0.95;P=0.004).具体来说,短期CS给药(≤3天)与临床结局的实质性改善相关(RR=0.24;95%CI:0.09-0.63;P=0.004),长期使用(≥8天)(RR=0.88;95%CI:0.77-0.99;P=0.04).此外,在中重度COVID-19患者中,给予地塞米松增加了28天的无呼吸机天数(平均差=1.92;95%CI:0.44~3.40;P=0.01).甲基强的松龙在改善临床结局方面也显示出显著的益处(RR=0.24;95%CI:0.09-0.63;P=0.004)。我们的荟萃分析表明,尽管住院COVID-19患者的28天死亡率没有显着差异,CSs的使用可能有利于改善中度或重度COVID-19患者的临床结局.与使用CSs相关的不良事件发生率没有显著增加。我们的荟萃分析提供了证据,尽管CSs可能不适合所有COVID-19患者,它们在重症COVID-19患者中可能是有效和安全的。因此,建议在COVID-19病例的个性化治疗中使用CSs,以改善临床结局,同时将不良事件降至最低.
    In the realm of acute respiratory infections, coronavirus disease-19 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), poses a global public health challenge. The application of corticosteroids (CSs) in COVID-19 remains a contentious topic among researchers. Accordingly, our team performed a comprehensive meta-analysis of randomized controlled trials (RCTs) to meticulously evaluate the safety and efficacy of CSs in hospitalized COVID-19 patients. To explore efficacy of CSs in the treatment of COVID-19 patients, we meticulously screened RCTs across key databases, including PubMed, Web of Science, Embase, Cochrane Library, ClinicalTrials.gov, as well as China\'s CNKI and Wanfang Data. We focused on assessing the 28 days mortality rates. We evaluated the data heterogeneity using the Chi-square test and I2 values, setting significance at 0.1 and 50%. Data from 21 RCTs involving 5721 participants were analyzed. The analysis did not demonstrate a significant association between CSs intervention and the 28 days mortality risk in hospitalized COVID-19 patients (relative risk [RR] = 0.93; 95% confidence interval [95% CI]: 0.84-1.03; P = 0.15). However, subgroup analysis revealed a significant reduction in 28 days mortality among patients with moderate-to-severe COVID-19 (RR at 0.85; 95% CI: 0.76-0.95; P = 0.004). Specifically, short-term CS administration (≤ 3 days) was associated with a substantial improvement in clinical outcomes (RR = 0.24; 95% CI: 0.09-0.63; P = 0.004), as was longer-term use (≥ 8 days) (RR = 0.88; 95% CI: 0.77-0.99; P = 0.04). Additionally, in patients with moderate-to-severe COVID-19, the administration of dexamethasone increased the number of 28 days ventilator-free days (Mean Difference = 1.92; 95% CI: 0.44-3.40; P = 0.01). Methylprednisolone also demonstrated significant benefits in improving clinical outcomes (RR = 0.24; 95% CI: 0.09-0.63; P = 0.004). Our meta-analysis demonstrated that although there is no significant difference in 28 days mortality rates among hospitalized COVID-19 patients, the use of CSs may be beneficial in improving clinical outcomes in moderate or severe COVID-19 patients. There was no significant increase in the occurrence of adverse events associated with the use of CSs. Our meta-analysis provides evidence that while CSs may not be suitable for all COVID-19 patients, they could be effective and safe in severely ill COVID-19 patients. Consequently, it is recommended to administer CSs for personalized treatments in COVID-19 cases to improve the clinical outcomes while minimizing adverse events.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    背景:多靶点神经保护药物DL-3-正丁苯酞(NBP)改善认知功能的疗效已在无痴呆的血管性认知障碍患者中得到证实。然而,其在阿尔茨海默病症状性痴呆前期患者中的疗效仍不确定。本研究旨在通过临床随机对照试验评估NBP改善轻度认知障碍(MCI)患者认知功能的有效性和安全性。
    方法:本研究为期12个月,随机化,双盲,安慰剂对照,多中心试验,涉及270名MCI患者。受试者被随机分配接受NBP软胶囊(200mg,每天三次)或安慰剂,分配比例为1:1。通过比较神经心理学的结果来评估NBP的有效性和安全性,两组之间的神经影像学和实验室检查。主要终点是12个月后阿尔茨海默病评估量表-认知子量表的变化。将监测所有患者的不良事件。
    背景:这项涉及人类参与者的研究已获得宣武医院伦理委员会的审查和批准(No.2017058)。参与者提供他们参与本研究的书面知情同意书。结果将在同行评审的医学期刊上发表,并在本地和国际会议上传播给医疗保健专业人员。
    方法:V3.0,2022年9月3日。
    背景:ChiCTR1800018362。
    BACKGROUND: The efficacy of multitarget neuroprotective drug DL-3-n-butylphthalide (NBP) in improving cognitive function has been confirmed in patients with vascular cognitive impairment without dementia. However, its efficacy in patients with symptomatic predementia phase of Alzheimer\'s disease remains uncertain. This study aims to evaluate the efficacy and safety of NBP in improving cognitive function in patients with mild cognitive impairment (MCI) through a clinical randomised controlled trail.
    METHODS: This study is a 12-month, randomised, double-blind, placebo-controlled, multicentric trial, involving 270 patients with MCI. Subjects are randomly assigned to receive either NBP soft capsule (200 mg, three times per day) or placebo with an allocation ratio of 1:1. The efficacy and safety of NBP are assessed by comparing the results of neuropsychological, neuroimaging and laboratory tests between the two groups. The primary endpoint is the change in Alzheimer\'s Disease Assessment Scale-Cognitive Subscale after 12 months. All patients will be monitored for adverse events.
    BACKGROUND: This study involving human participants has been reviewed and approved by Ethics Committee of Xuan Wu Hospital (No.2017058). The participants provide their written informed consent to participate in this study. Results will be published in peer-reviewed medical journals and disseminated to healthcare professionals at local and international conferences.
    METHODS: V 3.0, 3 September 2022.
    BACKGROUND: ChiCTR1800018362.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    目的:新辅助放化疗已成为局部晚期直肠癌患者的标准治疗方法。然而,个体之间的治疗反应差异很大,如何选择新辅助放化疗的最佳候选人至关重要.本研究旨在开发一种基于内窥镜图像的深度学习模型,用于预测局部晚期直肠癌对新辅助放化疗的反应。
    方法:在这项多中心观察研究中,回顾性获得了来自两个中国医学中心的患者的治疗前内镜图像,并构建了基于深度学习的肿瘤回归模型.基于肿瘤消退等级评估治疗反应,并将其定义为良好反应和非良好反应。在内部和外部测试集中评估了深度学习模型的预测性能。主要结果是治疗预测模型的准确性,通过AUC和准确性测量。
    结果:该深度学习模型实现了良好的预测性能。在内部测试集中,AUC和准确性分别为0.867(95%CI:0.847-0.941)和0.836(95%CI:0.818-0.896),分别。预测性能在外部测试集中得到了充分验证,模型的AUC为0.758(95%CI:0.724-0.834),准确度为0.807(95%CI:0.774-0.843).
    结论:基于内窥镜图像的深度学习模型对新辅助治疗反应具有出色的预测能力,突出了其指导个性化治疗的潜力。
    OBJECTIVE: Neoadjuvant chemoradiotherapy has been the standard practice for patients with locally advanced rectal cancer. However, the treatment response varies greatly among individuals, how to select the optimal candidates for neoadjuvant chemoradiotherapy is crucial. This study aimed to develop an endoscopic image-based deep learning model for predicting the response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer.
    METHODS: In this multicenter observational study, pre-treatment endoscopic images of patients from two Chinese medical centers were retrospectively obtained and a deep learning-based tumor regression model was constructed. Treatment response was evaluated based on the tumor regression grade and was defined as good response and non-good response. The prediction performance of the deep learning model was evaluated in the internal and external test sets. The main outcome was the accuracy of the treatment prediction model, measured by the AUC and accuracy.
    RESULTS: This deep learning model achieved favorable prediction performance. In the internal test set, the AUC and accuracy were 0.867 (95% CI: 0.847-0.941) and 0.836 (95% CI: 0.818-0.896), respectively. The prediction performance was fully validated in the external test set, and the model had an AUC of 0.758 (95% CI: 0.724-0.834) and an accuracy of 0.807 (95% CI: 0.774-0.843).
    CONCLUSIONS: The deep learning model based on endoscopic images demonstrated exceptional predictive power for neoadjuvant treatment response, highlighting its potential for guiding personalized therapy.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    背景:Meta分析主要关注基于运动的康复对术后结局的影响,而忽略了营养干预的作用。在这项研究中,我们通过研究以营养为基础的康复治疗对行食管切除术和胃切除术患者术后结局的影响,填补了这一空白.
    方法:五个电子数据库,即,PubMed,WebofScience,Embase,科克伦图书馆,和CINAHL,被搜查了。被诊断患有食管胃癌的成年人计划接受手术并接受了单模式或多模式康复治疗,至少一周的强制性营养干预,包括在内。森林地块用于从所包括的研究中提取和可视化数据。任何术后并发症的发生被认为是主要终点。
    结果:8项研究符合资格标准,5项随机对照试验(RCTs)和3项队列研究。总的来说,纳入661例患者。任何康复治疗,也就是说,单峰(仅营养)和多模式康复,术后并发症风险降低23%(95%置信区间[CI]=0.66-0.90).对于多模式前康复仅观察到类似的效果(风险比[RR]=0.78,95%CI=0.66-0.93);但是,对于单峰前康复并不重要.任何康复治疗都显着降低了住院时间(LOS)(加权平均差=-0.77,95%CI=-1.46至-0.09)。
    结论:基于营养的康复,特别是多模式的康复,对食管癌和胃切除术后的并发症有保护作用。我们的研究结果表明,康复治疗会稍微降低LOS;然而,这一发现没有临床意义.因此,需要额外严格的随机对照试验以进一步证实.
    BACKGROUND: Meta-analyses have primarily focused on the effects of exercise-based prehabilitation on postoperative outcomes and ignored the role of nutritional intervention. In this study, we filled this gap by investigating the effect of nutrition-based prehabilitation on the postoperative outcomes of patients who underwent esophagectomy and gastrectomy.
    METHODS: Five electronic databases, namely, PubMed, the Web of Science, Embase, Cochrane Library, and CINAHL, were searched. Adults diagnosed with esophagogastric cancer who were scheduled to undergo surgery and had undergone uni- or multimodal prehabilitation, with at least a week of mandatory nutritional intervention, were included. Forest plots were used to extract and visualize the data from the included studies. The occurrence of any postoperative complication was considered the primary endpoint.
    RESULTS: Eight studies met the eligibility criteria, with five randomized controlled trials (RCTs) and three cohort studies. In total, 661 patients were included. Any prehabilitation, that is, unimodal (only nutrition) and multimodal prehabilitation, collectively decreased the risk of any postoperative complication by 23% (95% confidence interval [CI] = 0.66-0.90). A similar effect was exclusively observed for multimodal prehabilitation (risk ratio [RR] = 0.78, 95% CI = 0.66-0.93); however, it was not significant for unimodal prehabilitation. Any prehabilitation significantly decreased the length of hospital stay (LOS) (weighted mean difference = -0.77, 95% CI = -1.46 to -0.09).
    CONCLUSIONS: Nutrition-based prehabilitation, particularly multimodal prehabilitation, confers protective effects against postoperative complications after esophagectomy and gastrectomy. Our findings suggest that prehabilitation slightly decreases LOS; however, the finding is not clinically significant. Therefore, additional rigorous RCTs are warranted for further substantiation.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    肠易激综合征(IBS)是一种常见的胃肠道疾病,肠道菌群失衡在其中起着重要作用。越来越多的研究探索涉及益生菌的治疗方案,益生元,合生元,和粪便微生物移植(FMT),但仍不确定哪种治疗方案更优。这项研究是在各种数据库和未发表的试验数据上进行的(截至2023年2月)。对IBS成年患者进行随机对照试验(RCT)筛选,比较干预措施与安慰剂。益生菌,益生元,合生元,使用均差和贝叶斯网络荟萃分析评估FMT和FMT的影响。在6528篇文章中,益生菌包括54个,7为益生元/合生元,FMT为6。益生菌显示改善IBS症状,特别是双歧杆菌和乳杆菌菌株。益生元和合生元没有显示出显著的改善。网络荟萃分析表明益生菌(OR=0.53,95%CI,0.48至0.59)和FMT(OR=0.46,95%CI,0.33至0.64)对IBS的有利作用,未报告严重不良事件。总之,益生菌和FMT对管理IBS有效,双歧杆菌和乳杆菌是优势菌株。然而,最有效的益生菌组合或菌株仍不清楚,而益生元和合生元没有显着改善。
    Irritable bowel syndrome (IBS) is a common gastrointestinal disorder with gut microbiota imbalance playing a significant role. There are increasing numbers of research studies exploring treatment options involving probiotics, prebiotics, synbiotics, and fecal microbiota transplantation (FMT), but it is still uncertain which treatment option is superior. The research was conducted on various databases and unpublished trial data (up to February 2023). Randomized controlled trials (RCTs) were screened for adult patients with IBS comparing interventions with placebo. Probiotics, prebiotics, synbiotics, and FMT were assessed for their impact using mean difference and Bayesian network meta-analysis. Out of 6528 articles, 54 were included for probiotics, 7 for prebiotics/synbiotics, and 6 for FMT. Probiotics showed improvement in IBS symptoms, particularly with Bifidobacterium and Lactobacillus strains. Prebiotics and synbiotics did not show significant improvement. Network meta-analysis indicated the favorable effects of probiotics (OR = 0.53, 95% CI, 0.48 to 0.59) and FMT (OR = 0.46, 95% CI, 0.33 to 0.64) on IBS, with no serious adverse events reported. In short, probiotics and FMT are effective for managing IBS, with Bifidobacterium and Lactobacillus being dominant strains. However, the most effective probiotic combination or strain remains unclear, while prebiotics and synbiotics did not show significant improvement.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Clinical Trial Protocol
    背景:不孕症在不育夫妇的两个成员中产生与不育相关的压力,尤其是对不孕妇女。一些研究证实了不孕症相关压力与不孕症治疗结果之间的负相关。在生育治疗期间,迫切需要有效的精神保健,但是缺乏有效的支持服务。减少不孕妇女的不孕压力,表达艺术治疗方案将由认证的国际表达艺术治疗师组织和实施。
    方法:本研究为随机对照试验。干预组的参与者将在基线调查后接受表达艺术疗法。表达艺术疗法将由认证的国际表达艺术治疗师领导。干预措施包括渐进式肌肉放松训练,音乐冥想和绘画疗法。对照组的参与者将接受常规护理。医院焦虑和抑郁量表(HADS)和生育问题量表(FPI)将用于调查焦虑,抑郁症,以及所有参与者在入院和出院时与不孕症相关的压力。
    结论:这项研究将验证表达艺术疗法对不育女性的有效性和效率。该结果将为不育妇女的精神保健策略提供新的知识。
    背景:ChiCTR,ChiCTR2300070618。2023年4月14日注册。
    BACKGROUND: Infertility produces infertility-related stress in both members of infertile couples, especially for infertile women. Some studies verified the negative relationship between infertility-related stress and outcomes of infertility treatments. Effective mental health care during fertility treatment is urgently needed, but there has been a lack of efficient support services. To reduce the infertility-related stress of infertile women, expressive art therapeutic schemes will be organized and implemented by certified international expressive art therapists.
    METHODS: This study is a randomized controlled trial. Participants in the intervention group will receive expressive art therapies after the baseline investigation. Expressive art therapies will be led by the certified international expressive art therapist. The interventions include progressive muscle relaxation training, music meditation and drawing therapy. Participants in the control group will receive routine care. The Hospital Anxiety and Depression Scale (HADS) and Fertility Problem Inventory (FPI) will be used to investigate the anxiety, depression, and infertility-related stress of all participants at admission and at discharge.
    CONCLUSIONS: This study will verify the effectiveness and efficiency of expressive art therapies for infertile women. The results will provide new knowledge on mental health care strategies for infertile women.
    BACKGROUND: ChiCTR, ChiCTR2300070618. Registered 14 April 2023.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    背景:髓内钉(IMN)和钢板内固定是胫骨远端骨折最常用的手术方式。然而,它们在功能结局和并发症方面的疗效优势仍存在争议.这里,我们进行了系统评价和荟萃分析,以比较这两种模式的疗效.
    方法:在PubMed,WebofScience,EMBASE,ClinicalTrials.gov,和Cochrane图书馆至2024年1月31日。加权平均差(WMD)和比值比(OR)以及相应的95%置信区间(CI)使用随机效应模型对连续和分类结果进行估计。分别。
    结果:共20个RCTs,包括1528例患者。与钢板固定相比,IMN显著缩短手术时间(WMD=-10.73分钟,95CI:-15.93至-5.52),工会时间(WMD=-1.56周,95CI:-2.82至-0.30),和部分(WMD=-1.71周,95CI:-1.91至-0.43)和完整(WMD=-2.61周,95CI:-3.53至-1.70)负重时间。IMN与伤口感染(OR=0.44,95CI:0.31-0.63)和二次手术(OR=0.72,95CI:0.55-0.95)的风险显着降低相关,但增加了不愈合(OR=1.53,95CI:1.02-2.30)和前膝疼痛(OR=3.94,95CI:1.68-9.28)的风险。骨不连的比率,延迟工会,两组的功能评估评分无显著差异.术后获得出色功能结果或出色和良好功能结果的患者百分比相当。
    结论:IMN和钢板内固定都是治疗胫骨远端骨折的有效方法。IMN似乎是首选,因为它赋予了更多的优势,但是畸形愈合和膝盖疼痛的发生率升高需要注意。固定方式的决定应针对特定的骨折,考虑到这些利弊。
    BACKGROUND: Intramedullary nail (IMN) and plate fixation are the most commonly used surgical modalities for distal tibia fractures. However, the superiority of their efficacy regarding functional outcomes and complications remains controversial. Here, we performed a systematic review and meta-analysis to compare the efficacy of these two modalities.
    METHODS: Randomized controlled trials (RCTs) comparing the efficacy of IMN and plate fixation in distal tibia fractures were searched in PubMed, Web of Science, EMBASE, ClinicalTrials.gov, and Cochrane Library up to January 31, 2024. Weighted mean difference (WMD) and odds ratio (OR) with corresponding 95% confidence interval (CI) were estimated using a random-effect model for continuous and categorical outcomes, respectively.
    RESULTS: A total of 20 RCTs comprising 1528 patients were included. Compared with plate fixation, IMN significantly shortened surgery time (WMD=-10.73 min, 95%CI: -15.93 to -5.52), union time (WMD=-1.56 weeks, 95%CI: -2.82 to -0.30), and partial (WMD=-1.71 weeks, 95%CI: -1.91 to -0.43) and full (WMD=-2.61 weeks, 95%CI: -3.53 to -1.70) weight-bearing time. IMN was associated with markedly reduced risk of wound infection (OR = 0.44, 95%CI: 0.31-0.63) and secondary procedures (OR = 0.72, 95%CI: 0.55-0.95), but increased the risk of malunion (OR = 1.53, 95%CI: 1.02-2.30) and anterior knee pain (OR = 3.94, 95%CI: 1.68-9.28). The rates of nonunion, delayed union, and functional assessment scores did not significantly differ between the two groups. The percentages of patients obtaining an excellent functional outcome or an excellent and good functional outcome post-operation were comparable.
    CONCLUSIONS: Both IMN and plate fixation are effective modalities for the surgical treatment of distal tibia fractures. IMN seems to be preferred since it confers more advantages, but the elevated rates of malunion and knee pain require attention. The decision on fixation modality should be tailored to the specific fracture, considering these pros and cons.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    目的:本研究旨在探讨使用不同类型的鞘管会如何影响学徒的首次消融手术。
    方法:15例阵发性心房颤动患者随机采用固定曲线,常规可操纵或可视化可操纵护套,并完全隔离肺静脉.所有消融都是由15名消融学徒进行的首次手术。分析了PVI期间透视检查的使用和导管稳定性。
    结果:固定曲线组的手术持续时间更长(116.8±27vs.62.2±17vs.60.4±17,p<0.001)。可视化鞘的X射线暴露最低(17.6±5vs.18.6±6vs.5.2±6,p<0.001)。CFSD差异显著,尤其是在LSPV的前部(7.90±2.90vs.5.04±2.18vs.4.52±2.40,p<0.001)和RSPV的后部(6.84±2.79vs.3.42±2.04vs.固定曲线组3.50±2.30,p<0.001)。固定曲线组LSPV前部的阻抗下降明显较小(8.74±3.02vs.11.49±5.48vs.12.57±5.96,p=0.005)。
    结论:即使是消融学徒的第一次消融手术,使用可操纵护套将显著缩短手术时间并提高导管稳定性,但只有可视化的可操纵护套才能减少透视时间。
    OBJECTIVE: This study aimed at exploring how using different kinds of sheaths will affect the very first ablation procedure of apprentices.
    METHODS: 15 patients with paroxysmal atrial fibrillation were randomized to used fixed-curve, conventional steerable or visualized steerable sheath, and received complete isolation of pulmonary veins. All ablations were the very first procedure performed by 15 ablation apprentices. The use of fluoroscopy and catheter stability during the PVI were analyzed.
    RESULTS: Procedure duration was much longer in the fixed-curve group (116.8 ± 27 vs. 62.2 ± 17 vs. 60.4 ± 17, p < 0.001). X-ray exposure was lowest with visualized sheath (17.6 ± 5 vs. 18.6 ± 6 vs. 5.2 ± 6, p < 0.001). CF SD differed significantly, especially at the anterior aspect of LSPV (7.90 ± 2.90 vs. 5.04 ± 2.18 vs. 4.52 ± 2.40, p < 0.001) and posterior aspect of RSPV (6.84 ± 2.79 vs. 3.42 ± 2.04 vs. 3.50 ± 2.30, p < 0.001) in the fixed-curve group. Impedance drop was significantly smaller in the fixed-curve group at the anterior aspect of LSPV (8.74 ± 3.02 vs. 11.49 ± 5.48 vs. 12.57 ± 5.96, p = 0.005).
    CONCLUSIONS: Even for the very first ablation procedure of an ablation apprentice, the use of steerable sheaths will significantly reduce the procedure duration and improve the catheter stability, but only visualized steerable sheath can reduce fluoroscopic time.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

公众号